- Home
- ENTA vs PRME Comparison
ENTA vs PRME Comparison
Compare ENTA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- PRME
- Stock Information
- Founded
- ENTA 1995
- PRME 2019
- Country
- ENTA United States
- PRME United States
- Employees
- ENTA N/A
- PRME N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- ENTA Health Care
- PRME Health Care
- Exchange
- ENTA Nasdaq
- PRME Nasdaq
- Market Cap
- ENTA 164.6M
- PRME 191.7M
- IPO Year
- ENTA 2013
- PRME 2022
- Fundamental
- Price
- ENTA $7.51
- PRME $3.75
- Analyst Decision
- ENTA Buy
- PRME Buy
- Analyst Count
- ENTA 5
- PRME 6
- Target Price
- ENTA $18.40
- PRME $9.38
- AVG Volume (30 Days)
- ENTA 173.3K
- PRME 5.5M
- Earning Date
- ENTA 08-08-2025
- PRME 08-08-2025
- Dividend Yield
- ENTA N/A
- PRME N/A
- EPS Growth
- ENTA N/A
- PRME N/A
- EPS
- ENTA N/A
- PRME N/A
- Revenue
- ENTA $64,462,999.00
- PRME $3,846,000.00
- Revenue This Year
- ENTA N/A
- PRME $104.12
- Revenue Next Year
- ENTA $2.75
- PRME $108.24
- P/E Ratio
- ENTA N/A
- PRME N/A
- Revenue Growth
- ENTA N/A
- PRME 550.76
- 52 Week Low
- ENTA $4.09
- PRME $1.11
- 52 Week High
- ENTA $15.92
- PRME $5.94
- Technical
- Relative Strength Index (RSI)
- ENTA 51.19
- PRME 51.37
- Support Level
- ENTA $7.15
- PRME $3.72
- Resistance Level
- ENTA $8.31
- PRME $5.15
- Average True Range (ATR)
- ENTA 0.48
- PRME 0.46
- MACD
- ENTA 0.01
- PRME -0.16
- Stochastic Oscillator
- ENTA 55.73
- PRME 13.64
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.